Chiron to Buy Vaccine Maker PowderJect
From Associated Press
As expected, Chiron Corp. said it would buy its British rival, PowderJect Pharmaceuticals, for about $878 million, increasing the biotech company’s share of the growing market for vaccines.
The cash deal would give Emeryville, Calif.-based Chiron control of Fluvirin, a top-selling flu vaccine.
Chiron’s shares fell 80 cents to $40.25 on Nasdaq.
